Liquid Biopsy Market Size, Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities and Forecast 2030
The liquid
biopsy market is expected to grow at a compound annual
growth rate (CAGR) of 18.3% over the forecast period. The market is expected to
reach a valuation of USD 4.1 billion globally in 2022. Developments in the
areas of cancer incidence and prevalence, non-invasive procedures, and patient
awareness of chronic disease treatment and demand for disease monitoring are
the main drivers of the market's growth.
A liquid biopsy is more practical and easy to use than a
conventional biopsy. It includes a range of methods such as circulating tumor
cells and circulating tumor DNA analysis. The industry is expanding due to the
application of tailored medicine, less intrusive testing, and early cancer
detection. Globally rising cancer incidence is fueling market expansion.
Technology developments are fueling the need for liquid biopsy.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/liquid-biopsy-market
Growth Drivers
The need for liquid biopsy is being driven by the growing
number of cancer patients globally and the growing popularity of minimally
invasive procedures among individuals. Government campaigns to raise awareness
of cancer are largely responsible for the market's rise. This approach is
becoming more convenient and appealing due to the growing desire for less
intrusive alternatives to traditional tissue biopsies, which are risky and
extremely uncomfortable. It makes it possible to identify particular biomarkers
linked to the illnesses of particular patients, allowing for individualized
treatment plans based on each person's own genetic profile.
Liquid biopsies are one of the sensitive diagnostic methods
that are becoming more and more necessary for early identification and
monitoring of cancer, given the rising incidence of the disease worldwide.
Adoption rates among healthcare professionals and institutions are anticipated
to rise as more clinical evidence shows how useful liquid biopsies are in
guiding treatment decisions and improving patient outcomes.
The need for non-invasive diagnostic techniques like liquid
biopsies for early illness identification and monitoring is rising due to the
rising incidence of cancer worldwide. Liquid
biopsies help physicians make educated judgments about
therapy selection and disease progression by giving them access to real-time
information on tumor dynamics and treatment response.
Segmentation
By Product and Services
· Assay
Kits
· Instruments
· Services
By Application
· Cancer
· Lung
Cancer
· Breast
Cancer
· Colorectal
Cancer
· Prostate
Cancer
· Melanoma
· Other
Cancers
· Non-Cancer
applications
· Non-Invasive
Pre-Natal Testing
· Organ
Transplantation
· Infectious
Disease Testing
By Sample Type
· Blood
· Other
Sample Types
Regional Outlook
· Asia
Pacific
· North
America
· Latin
America
· Europe
· Middle
East and Africa
Key Players
· Thermo
Fisher Scientific Inc
· Myriad
Genetic Inc
· Guardant
Health Inc
· Qiagen
N.V.
· F.
Hoffman La Roche Ltd.
· ANGLE
Plc
· Biocept
Inc
· Lucence
Health Inc
· Freename,
Holdings Inc
· Oncimmune
Holdings Plc
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/liquid-biopsy-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment